ArticleFrontiers in immunology2025
Multi-omics analyses construct an inflammatory response based prognostic gene signature for cervical cancer and suggest tumor infiltrating monocytes subgroups as key players.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tupaia belangeri better reflects the typical symptoms of Chikungunya virus infection than mice: A comparative study.Virologica Sinica · 2026Article
- Multilevel Transcriptomic Association Analysis Reveals Key Genes and Potential Mechanisms in Endometrial, Ovarian, and Cervical Cancers.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory response in the tumor micro-environment contributes to the progression and treatment response of various types of cancers. However, for cervical cancer, a type of cancer initiated by the infection of HPV, the clinical relevance of the inflammatory response and the underlying mechanisms remain to be elucidated. Methods: The RNA-seq and clinical data of cervical cancer patients in several public datasets was used to construct and validate a prognostic gene signature based on the inflammatory response related genes. Risk stratification of patients was carried out according to this gene signature, and bioinformatic analyses were conducted to depict the immune landscape, identify the enriched biological pathways and predict patients' treatment response. Single-cell and bulk RNA-seq data was jointly analysed to explore the underlying cellular and molecular mechanisms of the gene signature. The RNA-seq data of our own cohort and additional public datasets was used to further validate the findings made in this study. Results: A prognostic gene signature consisting of 16 inflammatory response related genes was constructed and successfully validated on multiple testing datasets. Patients in the low-risk group defined by this gene signature had significantly better survival (hazard ratio [HR]=0.48, 95% Confidence Interval [CI]: 0.275-0.85; Multivariate analysis on the CGCI testing dataset). The two risk groups had different immune landscapes, enriched biological pathways and predicted sensitivity to chemo-, radio- and immune-therapy. Two subgroups of tumor infiltrating monocytes with possibly opposite functions might be actively involved in the inflammatory response. SERPINE1 and ITGA5 expressed on endothelial cells might have synergic effects and regulate the infiltration of monocytes and macrophages. Findings were successfully validated with our own RNA-seq data and on additional public datasets. Conclusion: The inflammatory response in the tumor micro-environment of cervical cancer, possibly jointly regulated by multiple TIM subgroups, is associated with the prognosis and treatment response of cervical cancer patients and may be potential treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.